Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
FinMin seeks more time for PSBs to meet MPS norm

6h freepressjournal.in
New Delhi : The finance ministry may approach markets regulator Sebi to seek relaxation on the minimum 25 per cent public shareholding norm for some state banks (PSBs).
INDIANB IOB 500116 UDBKL IDBI UBLS 532418 532814 532505 CNRYY 532388 SYNDIBANK 532276 532121 532483 UBLA UCOBANK CANBK DENABANK ANDHRABANK

0
PSU bank stocks surge up to 11% on capital infusion reports

2018-07-17 thehindubusinessline
PSU bank stocks today surged up to 11 per cent amid reports that the finance ministry is likely to infuse about Rs 10,000 crore within a few days in some state-owned lenders to help them meet regulatory capital requirement.
INDIANB IOB ALBK 532418 532814 CNRYY 532179 532388 PNJZY 532121 532483 532461 CRPKY 532480 PNB CORPBANK CANBK DENABANK ANDHRABANK

0
FinMin seeks more time for PSBs to meet MPS norm

2018-07-16 freepressjournal.in
New Delhi : The finance ministry may approach markets regulator Sebi to seek relaxation on the minimum 25 per cent public shareholding norm for some state banks (PSBs).
INDIANB IOB 500116 UDBKL IDBI UBLS 532418 532814 532505 CNRYY 532388 SYNDIBANK 532276 532121 532483 UBLA UCOBANK CANBK DENABANK ANDHRABANK

0
PSU banks plan to raise over Rs 50k crore equity capital in FY19

2018-07-08 moneycontrol
Public sector banks are planning to tap the markets to raise more than Rs 50,000 crore this fiscal to shore up their capital base for business growth and meeting regulatory global risk norms.
ALBK 532505 CNRYY 532179 SYNDIBANK 532276 532121 532483 CRPKY 532480 CORPBANK UCOBANK CANBK DENABANK

4
Over 160 stocks hit fresh 52-week low on BSE; DEN Networks, Hathway, BHEL, Andhra Bank top losers

2018-07-06 moneycontrol
The Indian benchmark indices are trading on a positive note this Friday afternoon with the Nifty adding 47 points and is trading at 10,796 mark. The Sensex is trading higher by 147 points at 35,722.
BAJAJ-AUTO 532938 CAPF 532418 532977 514034 532953 533137 VISASTEEL DEN 533644 532121 INOXWIND JBFIND VGUARD 500477 500570 BEL 500493 TATAMOTORS BHARATFORG ASHOKLEY BHQRY CONART 532721 AKLD FINOLEXIND UJAAS 501455 500940 522231 500049 GREAVESCOT 539083 DENABANK AKLS ANDHRABANK TTM

1
Closing Bell: Banks, RIL lift Sensex 267 pts; Nifty ends above 10,750 despite weak Asia

2018-07-04 moneycontrol
Global Update: Asian markets ended in the red with China's Shanghai Composite losing a percent after recording gains in the previous session. Trade tensions remained in the spotlight ahead of a looming tariff deadline, reports CNBC.
BAJAJ-AUTO KOHINOOR MUTHOOTFIN BHRYY 500325 UBL RELIANCE 532978 532977 533398 SRTRANSFIN 532478 511218 532783 532187 532121 506690 534816 RIGD SRRQY HDFCBANK BJJQY INFRATEL RLNIY 500034 UNICHEMLAB INDUSINDBK UBHOLDINGS 539126 UNBWY MEP 512559 BAJAJFINSV BAJFINANCE HDB 500180 DENABANK 507458 DAAWAT

0
Market Live: Nifty at day#39;s high, Sensex up over 250 pts; Bajaj Auto, Bharti Infratel top gainers

2018-07-04 moneycontrol
Buzzing: Unichem Laboratories share price rallied more than 5 percent intraday after the company received final ANDA approval for its Montelukast Chewable tablets, 4 mg and 5 mg from the United States Food and Drug Administration to market in the US.
BAJAJ-AUTO KOHINOOR BHRYY 500325 UBL RELIANCE 532978 532977 SRTRANSFIN 532478 511218 532783 532121 506690 534816 RIGD SRRQY BJJQY INFRATEL RLNIY 500034 UNICHEMLAB UBHOLDINGS UNBWY 512559 506022 BAJAJFINSV BAJFINANCE PRAKASH DENABANK 507458 DAAWAT

4
Market Live: Sensex up 150 pts despite global weakness; HDFC twins, RIL lead

2018-07-04 moneycontrol
Europe Update: European stocks were slightly lower Wednesday morning, amid elevated tensions between the US and China over looming trade tariffs and investment restrictions.
BAJAJ-AUTO KOHINOOR 500325 533271 UBL RELIANCE ASHOKA 532978 532977 532712 SRTRANSFIN 532478 511218 532783 500470 532121 RCOM RIGD SRRQY BJJQY 500570 TATAMOTORS 509488 RLNIY 500034 GRAPHITE UBHOLDINGS 532967 UNBWY KIRIINDUS BHEL 512559 506022 BAJAJFINSV BAJFINANCE TTST TATASTEEL TATLY PRAKASH BRHTY 500103 DENABANK 507458 DAAWAT TTM

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...